Enliven Therapeutics shared updated early data for ELVN-001 in previously treated chronic myeloid leukemia (CML), with results discussed for a proposed go-forward 80 mg once-daily cohort. The company reported major molecular response rates reaching 48% at 24 weeks, and the update prompted renewed expectations for a phase III study. Analysis cited by investors pointed to an increased response rate compared with prior reporting, and the program is positioned around a BCR::ABL1 molecular driver. The company also suggested phase III could start in the second half of the year, contingent on further progress. The update adds to a small set of later-stage CML strategies competing on depth of response and tolerability among patients with limited options after prior therapy.